DOCSLIB.ORG

Sofosbuvir with Daclatasvir and the Outcomes of Patients with COVID-19

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sofosbuvir with Daclatasvir and the Outcomes of Patients with COVID-19 Original research Postgrad Med J: first published as 10.1136/postgradmedj-2021-140287 on 8 June 2021. Downloaded from Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta- analysis with GRADE assessment Ahmad Fariz Malvi Zamzam Zein ,1,2 Catur Setiya Sulistiyana,1,2 Wilson Matthew Raffaello,3 Arief Wibowo,4 Raymond Pranata 3,4 1Department of Internal ABSTRACT indicate the potential activities of SOF and DCV on 9 10 Medicine, Faculty of Medicine Purpose This systematic review and meta- analysis SARS- CoV-2 RdRp, although the mixed results. Universitas Swadaya Gunung aimed to evaluate the effect of sofosbuvir/daclatasvir Several clinical studies indicate the potential benefit Jati, Cirebon, Indonesia 9 11 12 2Department of Internal (SOF/DCV) on mortality, the need for intensive care unit of SOF/DCV in patients with COVID-19. Medicine, Waled General (ICU) admission or invasive mechanical ventilation (IMV) These drugs have relatively mild side effects and are Hospital, Cirebon, Indonesia affordable. Thus, it can be used as a routine treat- 3 and clinical recovery in patients with COVID-19. Faculty of Medicine Universitas 9 13 Methods We performed a systematic literature ment if proven to be effective. This systematic Pelita Harapan, Tangerang, Indonesia search through the PubMed, Scopus and Embase review and meta- analysis aims to evaluate the effect 4Department of Cardiology from the inception of databases until 6 April 2021. of SOF/DCV on mortality, the need for intensive and Vascular Medicine, Faculty The intervention group was SOF/DCV, and the control care unit (ICU) admission or invasive mechanical of Medicine Universitas group was standard of care. The primary outcome was ventilation (IMV) and clinical recovery in patients Padjadjaran, Rumah Sakit with COVID-19. Umum Pusat Hasan Sadikin, mortality, defined as clinically validated death. The Bandung, Jawa Barat, Indonesia secondary outcomes were (1) the need for ICU admission or IMV and (2) clinical recovery. The pooled effect MATERIALS AND METHODS Correspondence to estimates were reported as risk ratios (RRs). This is a Preferred Reporting Items for Systematic Dr Ahmad Fariz Malvi Zamzam Results There were four studies with a total of 231 Reviews and Meta- Analyses compliant systematic Zein, Universitas Swadaya patients in this meta-analysis . Three studies were review and meta- analysis. This study is registered in Gunung Jati, Cirebon 45132, Indonesia; randomised controlled trial, and one study was non- PROSPERO (blinded for peer review). fariz_ zein_ dr@ yahoo. com randomised. SOF/DCV was associated with lower 2 mortality (RR: 0.31 (0.12, 0.78); p=0.013; I : 0%) and Search strategy and study selection Received 12 April 2021 reduced need for ICU admission or IMV (RR: 0.35 (0.18, We performed a systematic literature search 2 Accepted 21 May 2021 0.69); p=0.002; I : 0%). Clinical recovery was achieved through PubMed, Scopus and Embase using the more frequently in the SOF/DCV (RR: 1.20 (1.04, 1.37); terms ‘(SARS- CoV-2 or 2019- nCoV or COVID-19) 2 p=0.011; I : 21.1%). There was a moderate certainty of and (sofosbuvir or daclatasvir or Sofosbuvir/daclat- evidence for mortality and need for ICU/IMV outcome, asvir)’ from the inception of databases until 6 April http://pmj.bmj.com/ and a low certainty of evidence for clinical recovery. The 2021. Screening of title/abstracts were performed absolute risk reductions were 140 fewer per 1000 for by two independent authors. The eligibility of the mortality and 186 fewer per 1000 for the need for ICU/ articles was assessed based on the inclusion and IMV. The increase in clinical recovery was 146 more per exclusion criteria. Discrepancies that arose were 1000. resolved by discussion. Conclusion SOF/DCV may reduce mortality rate and need for ICU/IMV in patients with COVID-19 while Inclusion and exclusion criteria on September 27, 2021 by guest. Protected copyright. increasing the chance for clinical recovery. Studies that match the following criteria were Protocol registration PROSPERO: CRD42021247510. included: (1) randomised controlled trials (RCTs) or observational studies in patients with COVID- 19, (2) comprise of SOF/DCV arm and a control INTRODUCTION arm and (3) reporting either (a) mortality or (b) COVID-19 remains one of the most prevalent the need for ICU admission or IMV or (c) clinical diseases globally despite the best effort to contain recovery. them.1 Although most patients have mild–moderate Studies that match one of the following criteria © Author(s) (or their clinical symptoms, a significant proportion of them were excluded: (1) conference papers, (2) abstract- employer(s)) 2021. No developed lethal acute complications.2–4 Optimal only publications, (3) review articles and (4) commercial re- use. See rights medications for COVID-19 remained poorly commentaries. We did not impose any language and permissions. Published restriction for this systematic review. by BMJ. defined, and many completed trials showed nega- tive results.5 To cite: Zein AFMZ, SARS- CoV-2 is a positive- sense single- stranded Data extraction Sulistiyana CS, Raffaello WM, RNA virus that relies on RNA- dependent RNA- Two authors independently extracted data from the et al. Postgrad Med J Epub 6 ahead of print: [please polymerase (RdRp) for viral replication. Sofos- studies for the first author, study design, country include Day Month Year]. buvir/daclatasvir (SOF/DCV) is a direct-acting of origin, setting of the study (inpatients or outpa- doi:10.1136/ antiviral drug that has been shown to inhibit RdRp tients), details and dosing of the intervention group, postgradmedj-2021-140287 of hepatitis C virus (HCV).7 8 Preclinical studies details and dosing of the control group, sample size, Zein AFMZ, et al. Postgrad Med J 2021;0:1–6. doi:10.1136/postgradmedj-2021-140287 1 Original research Postgrad Med J: first published as 10.1136/postgradmedj-2021-140287 on 8 June 2021. Downloaded from age, gender, diabetes, chronic obstructive pulmonary disease, Statistical analysis chronic kidney diseases, cardiovascular diseases and the labo- DerSimonian Laird random- effects meta- analysis was used to ratory values, including haematology parameters and liver and calculate the pooled RRs for mortality, need for ICU admis- renal functions. Discrepancies were resolved by discussion. sion/IMV and clinical recovery in the SOF/DCV compared with the control group. P values (two- tailed) of ≤0.05 were consid- Risk of bias assessment ered statistically significant. To evaluate heterogeneity, we used We used the Cochrane Risk of Bias Assessment for RCTs14 and Cochran’s Q test and I2 statistics; I2 values above 50% and p Newcastle- Ottawa Scale (NOS).15 NOS comprises of selection, value below 0.10 indicate significant heterogeneity. Sensitivity comparability and outcome. Cochrane Risk of Bias Assessment analysis was performed for outpatient studies. STATA V.16.0 assessed the possibility for selection, performance, detection, was used to perform the statistical analysis. attrition, selective reporting and other biases. Discrepancies during the process were resolved by discussion. Grading of Recommendations Assessment, Development and Evaluation RESULTS framework was used to determine the certainty of evidence. Baseline characteristics There were four studies with a total of 231 patients in this Intervention and outcome systematic review and meta- analysis (figure 1).9 11 12 16 Three The intervention group was SOF/DCV, defined as 400 mg SOF studies were RCT, and one study was non- randomised (table 1). and 60 mg DCV to treat COVID-19. The control group was the standard of care or placebo set by each trial/studies. The primary outcome was mortality, defined as clinically validated death. SOF/DCV and outcomes The pooled effect estimate was reported as risk ratio (RR). SOF/DCV administration was associated with reduced mortality 2 The secondary outcomes were (1) the need for ICU admission (RR: 0.31 (0.12, 0.78)], p=0.013; I : 0%, p=0.400) (figure 2). or IMV and (2) clinical recovery. Clinical recovery was defined Use of SOF/DCV was associated with reduced need for ICU 2 as resolution of fever (≤37.2°C) with a normal respiratory rate admission or IMV (RR: 0.35 (0.18, 0.69), p=0.002; I : 0%, (≤24 breaths/min) and oxygen saturation (≥94%) without the p=0.700) (figure 3). Clinical recovery was achieved more need for supplementary oxygen therapy for at least 24 hours or frequently in the SOF/DCV (RR: 1.20 (1.04, 1.37), p=0.011; I2: can be discharged from the hospital based on clinical improve- 21.1%, p=0.284) (figure 4). Sensitivity analysis by removal of ment. The pooled effect estimate was reported as RRs. outpatient setting (Roozbeh et al16 2021) showed that SOF/DCV http://pmj.bmj.com/ on September 27, 2021 by guest. Protected copyright. Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart. 2 Zein AFMZ, et al. Postgrad Med J 2021;0:1–6. doi:10.1136/postgradmedj-2021-140287 Original research Postgrad Med J: first published as 10.1136/postgradmedj-2021-140287 on 8 June 2021. Downloaded from Table 1 Baseline characteristics of the included studies Eslami et al11 2020 Abbaspour Kasgari et al12 2020 Roozbeh et al16 2021 Sadeghi et al9 2020 Study design Open- label parallel RCT RCT RCT Trial registration number IRCT20200324046850N2 IRCT20200328046886N1 IRCT20200403046926N1 IRCT20200128046294N2 Country of origin Iran Iran Iran Iran Setting Inpatients Inpatients Outpatients Inpatients COVID-19 severity Severe
Load more

Recommended publications
  • Daklinza, INN-Daclatasvir
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Daklinza 30 mg film-coated tablets Daklinza 60 mg film-coated tablets Daklinza 90 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Daklinza 30 mg film-coated tablets Each film-coated tablet contains daclatasvir dihydrochloride equivalent to 30 mg daclatasvir. Daklinza 60 mg film-coated tablets Each film-coated tablet contains daclatasvir dihydrochloride equivalent to 60 mg daclatasvir. Daklinza 90 mg film-coated tablets Each film-coated tablet contains daclatasvir dihydrochloride equivalent to 90 mg daclatasvir. Excipient(s) with known effect Each 30-mg film-coated tablet contains 58 mg of lactose (as anhydrous). Each 60-mg film-coated tablet contains 116 mg of lactose (as anhydrous). Each 90-mg film-coated tablet contains 173 mg of lactose (as anhydrous). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Daklinza 30 mg film-coated tablets Green biconvex pentagonal of dimensions 7.2 mm x 7.0 mm, debossed tablet with "BMS" on one side and "213" on the other side. Daklinza 60 mg film-coated tablets Light green biconvex pentagonal of dimensions 9.1 mm x 8.9 mm, debossed tablet with "BMS" on one side and "215" on the other side. Daklinza 90 mg film-coated tablets Light green biconvex round of dimension 10.16 mm diameter, embossed tablet with "BMS" on one side and "011" on the other side.
    [Show full text]
  • COVID-19) Pandemic on National Antimicrobial Consumption in Jordan
    antibiotics Article An Assessment of the Impact of Coronavirus Disease (COVID-19) Pandemic on National Antimicrobial Consumption in Jordan Sayer Al-Azzam 1, Nizar Mahmoud Mhaidat 1, Hayaa A. Banat 2, Mohammad Alfaour 2, Dana Samih Ahmad 2, Arno Muller 3, Adi Al-Nuseirat 4 , Elizabeth A. Lattyak 5, Barbara R. Conway 6,7 and Mamoon A. Aldeyab 6,* 1 Clinical Pharmacy Department, Jordan University of Science and Technology, Irbid 22110, Jordan; [email protected] (S.A.-A.); [email protected] (N.M.M.) 2 Jordan Food and Drug Administration (JFDA), Amman 11181, Jordan; [email protected] (H.A.B.); [email protected] (M.A.); [email protected] (D.S.A.) 3 Antimicrobial Resistance Division, World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland; [email protected] 4 World Health Organization Regional Office for the Eastern Mediterranean, Cairo 11371, Egypt; [email protected] 5 Scientific Computing Associates Corp., River Forest, IL 60305, USA; [email protected] 6 Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield HD1 3DH, UK; [email protected] 7 Institute of Skin Integrity and Infection Prevention, University of Huddersfield, Huddersfield HD1 3DH, UK * Correspondence: [email protected] Citation: Al-Azzam, S.; Mhaidat, N.M.; Banat, H.A.; Alfaour, M.; Abstract: Coronavirus disease 2019 (COVID-19) has overlapping clinical characteristics with bacterial Ahmad, D.S.; Muller, A.; Al-Nuseirat, respiratory tract infection, leading to the prescription of potentially unnecessary antibiotics. This A.; Lattyak, E.A.; Conway, B.R.; study aimed at measuring changes and patterns of national antimicrobial use for one year preceding Aldeyab, M.A.
    [Show full text]
  • Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Subjects Aged 65 Years Or Older
    AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOLOGY, VOL. 63, NO. 4, 2016 Safety and Efficacy of Ledipasvir/ Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Subjects Aged 65 Years or Older Sammy Saab,1 Sarah H. Park,1 Masashi Mizokami,2 Masao Omata,3 Alessandra Mangia,4 Ed Eggleton,5 Yanni Zhu,5 Steven J. Knox,5 Phil Pang,5 Mani Subramanian,5 Kris Kowdley,6 and Nezam H. Afdhal7 Elderly subjects have been historically underrepresented in clinical trials involving antiviral hepatitis C therapies. The aim of this analysis was to retrospectively evaluate the safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF) by age groups of <65 years versus 65 years among subjects enrolled in phase 3 trials. Four open-label phase 3 clinical trials evaluated the safety and efficacy of LDV/SOF with or without ribavirin (RBV) for the treatment of genotype 1 chronic hepatitis C virus. Sustained virological response at 12 weeks, treatment-emergent adverse events (AEs), and graded laboratory abnor- malities were analyzed according to age group. Of the 2293 subjects enrolled in four phase 3 trials, 264 (12%) were 65 years of age, of whom 24 were aged 75 years. Sustained virological response at 12 weeks was achieved by 97% (1965/ 2029) of subjects aged <65 years and 98% (258/264) of subjects aged 65 years. The most common AEs in both LDV/ SOF groups that occurred in 10% of subjects were headache and fatigue. The rate of study discontinuation due to AEs was similar in the two age cohorts.
    [Show full text]
  • (MGH) COVID-19 Treatment Guidance
    Version 8.0 4/28/2021 10:00AM © Copyright 2020 The General Hospital Corporation. All Rights Reserved. Massachusetts General Hospital (MGH) COVID-19 Treatment Guidance This document was prepared (in March, 2020-April, 2021) by and for MGH medical professionals (a.k.a. clinicians, care givers) and is being made available publicly for informational purposes only, in the context of a public health emergency related to COVID-19 (a.k.a. the coronavirus) and in connection with the state of emergency declared by the Governor of the Commonwealth of Massachusetts and the President of the United States. It is neither an attempt to substitute for the practice of medicine nor as a substitute for the provision of any medical professional services. Furthermore, the content is not meant to be complete, exhaustive, or a substitute for medical professional advice, diagnosis, or treatment. The information herein should be adapted to each specific patient based on the treating medical professional’s independent professional judgment and consideration of the patient’s needs, the resources available at the location from where the medical professional services are being provided (e.g., healthcare institution, ambulatory clinic, physician’s office, etc.), and any other unique circumstances. This information should not be used to replace, substitute for, or overrule a qualified medical professional’s judgment. This website may contain third party materials and/or links to third party materials and third party websites for your information and convenience. Partners is not responsible for the availability, accuracy, or content of any of those third party materials or websites nor does it endorse them.
    [Show full text]
  • Effectiveness and Safety of Sofosbuvir Plus Ribavirin for the Treatment of HCV Genotype 2 Infection
    Hepatology ORIGINAL ARTICLE Effectiveness and safety of sofosbuvir plus ribavirin Gut: first published as 10.1136/gutjnl-2016-311609 on 13 July 2016. Downloaded from for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study Tania M Welzel,1 David R Nelson,2 Giuseppe Morelli,2 Adrian Di Bisceglie,3 Rajender K Reddy,4 Alexander Kuo,5 Joseph K Lim,6 Jama Darling,7 Paul Pockros,8 Joseph S Galati,9 Lynn M Frazier,10 Saleh Alqahtani,11 Mark S Sulkowski,11 Monika Vainorius,7 Lucy Akushevich,7 Michael W Fried,7 Stefan Zeuzem,1 for the HCV-TARGET Study Group ► Additional material is ABSTRACT published online only. To view Objective Due to a high efficacy in clinical trials, Significance of this study please visit the journal online sofosbuvir (SOF) and ribavirin (RBV) for 12 or 16 weeks (http://dx.doi.org/10.1136/ gutjnl-2016-311609). is recommended for treatment of patients with HCV genotype (GT) 2 infection. We investigated safety and What is already known on this subject? For numbered affiliations see effectiveness of these regimens for GT2 in HCV-TARGET ▸ fi end of article. Due to a high ef cacy in clinical trials, the participants. all-oral combination of sofosbuvir (SOF) and Correspondence to Design HCV-TARGET, an international, prospective ribavirin (RBV) for 12 weeks is currently Dr Tania Mara Welzel, JW observational study evaluates clinical practice data on considered standard of care in patients with Goethe University Hospital, novel antiviral therapies at 44 academic and 17 HCV genotype 2 (GT2) infection.
    [Show full text]
  • Anti-Inflammatory Effects of Amantadine and Memantine
    Journal of Personalized Medicine Communication Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19? Félix Javier Jiménez-Jiménez 1,* , Hortensia Alonso-Navarro 1 , Elena García-Martín 2 and José A. G. Agúndez 2 1 Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, E-28500 Madrid, Spain; [email protected] 2 University Institute of Molecular Pathology Biomarkers, UNEx. ARADyAL Instituto de Salud Carlos III, E-10071 Cáceres, Spain; [email protected] (E.G.-M.); [email protected] (J.A.G.A.) * Correspondence: [email protected]; Tel.: +34-636968395 Received: 2 October 2020; Accepted: 6 November 2020; Published: 9 November 2020 Abstract: We have reviewed current data on the anti-inflammatory effects of amantadine and memantine in clinical and in vivo models of inflammation, and we propose that these effects have potential interest for the treatment of the SARS-CoV-2 infection (COVID-19 disease). To that end, we performed a literature search using the PubMed Database from 1966 up to October 31 2020, crossing the terms “amantadine” and “memantine” with “inflammation” and “anti-inflammatory”. Amantadine and/or memantine have shown anti-inflammatory effects in chronic hepatitis C, in neuroinflammation induced by sepsis and by lipopolysaccharides, experimental models of multiple sclerosis, spinal cord injury, and respiratory diseases. Since the inflammatory response is one of the main pathogenetic mechanisms in the progression of the SARS-CoV-2 infection, anti-inflammatory effects of amantadine and memantine could be hypothetically useful in the treatment of this condition. This potential utility deserves further research. Keywords: amantadine; memantine; anti-inflammatory effects; SARS-Cov-2; COVID-19; therapy 1.
    [Show full text]
  • Clinical Trial Details (PDF Generation Date :- Tue, 07 Sep 2021 08
    PDF of Trial CTRI Website URL - http://ctri.nic.in Clinical Trial Details (PDF Generation Date :- Wed, 29 Sep 2021 20:12:22 GMT) CTRI Number CTRI/2020/12/029855 [Registered on: 16/12/2020] - Trial Registered Prospectively Last Modified On 30/03/2021 Post Graduate Thesis No Type of Trial Interventional Type of Study Biological Study Design Other Public Title of Study Phase III, Randomized, Controlled, Open-Label Study of Pegylated Interferon Alfa-2b With SARS-CoV-2 Scientific Title of A Phase III, Randomized, Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Study Pegylated Interferon Alfa-2b In the Treatment of Adult Patients Diagnosed With SARS-CoV-2 (COVID-19). Secondary IDs if Any Secondary ID Identifier PEGI.20.005 Versoion 02,02 December 2020 Protocol Number Details of Principal Details of Principal Investigator Investigator or overall Name Dr Manjunath K Trial Coordinator (multi-center study) Designation Deputy General Manager Affiliation Cadila Healthcare Limited Address Zydus Research Center, Survey No. 396/403, Sarkhej-Bavla National Highway No.8A Moraiya, Ahmedabad - 382213 Ahmadabad GUJARAT 382213 India Phone Fax Email [email protected] Details Contact Details Contact Person (Scientific Query) Person (Scientific Name Dr Kevinkumar Kansagra Query) Designation General Manager Affiliation Cadila Healthcare Limited Address Zydus Research Center, Survey No. 396/403, Sarkhej-Bavla National Highway No.8A Moraiya, Ahmedabad - 382213 Ahmadabad GUJARAT 382213 India Phone Fax Email [email protected] Details Contact Details Contact Person (Public Query) Person (Public Query) Name Dr Balaji More Designation Senior General Manager Affiliation Cadila Healthcare Limited Address Zydus Research Center, Survey No.
    [Show full text]
  • SOVALDI® (Sofosbuvir)
    HIGHLIGHTS OF PRESCRIBING INFORMATION --------------------------------CONTRAINDICATIONS-----------------------------­ These highlights do not include all the information needed to use • When used in combination with peginterferon alfa/ribavirin or SOVALDI safely and effectively. See full prescribing information ribavirin alone, all contraindications to peginterferon alfa and/or for SOVALDI. ribavirin also apply to SOVALDI combination therapy. (4) ® SOVALDI (sofosbuvir) tablets, for oral use -------------------------WARNINGS AND PRECAUTIONS---------------------­ Initial U.S. Approval: 2013 • Bradycardia with amiodarone coadministration: Serious symptomatic bradycardia may occur in patients taking ------------------------------RECENT MAJOR CHANGES-----------------------­ amiodarone and SOVALDI in combination with another direct Indications and Usage (1) 08/2015 acting antiviral (DAA), particularly in patients also receiving beta Dosage and Administration (2.1, 2.2) 08/2015 blockers, or those with underlying cardiac comorbidities and/or Contraindications (4) 08/2015 advanced liver disease. Coadministration of amiodarone with Warnings and Precautions (5.1) 03/2015 SOVALDI in combination with another DAA is not recommended. Warnings and Precautions (5.2, 5.3, 5.4) 08/2015 In patients without alternative, viable treatment options, cardiac -------------------------------INDICATIONS AND USAGE------------------------­ monitoring is recommended. (5.1, 6.2,7.1) SOVALDI is a hepatitis C virus (HCV) nucleotide analog NS5B • Use with other drugs containing
    [Show full text]
  • 2015 Hepatitis C Second Generation Antivirals (Harvoni [Ledipasvir/Sofosbuvir], and Viekira Pak [Ombitasvir/Paritaprevir/Ritonavir
    2015 Hepatitis C Second Generation Antivirals (Harvoni [ledipasvir/sofosbuvir], and Viekira Pak [ombitasvir/paritaprevir/ritonavir + dasabuvir ]) Prior Authorization – Through Preferred Agents Program Summary 2015 Hepatitis C Second Generation Antivirals (Harvoni [ledipasvir/sofosbuvir], and Viekira Pak [ombitasvir/paritaprevir/ritonavir + dasabuvir]) Prior Authorization – Through Preferred Oral Agent(s) The Hepatitis C First Generation, Hepatitis C Second Generation and Sovaldi Prior Authorization Programs must be implemented together. OBJECTIVE The intent of the Hepatitis C second generation antiviral Prior Authorization (PA) program is to appropriately select patients for therapy according to the Food and Drug Administration (FDA) approved product labeling and/or clinical guidelines and/or clinical studies. The PA process will evaluate the use of these agents when there is supporting clinical evidence of Class IIa, Level C or better for their use. Patients requesting Harvoni that are treatment naïve, non-cirrhotic and with an initial viral load < 6 M IU/mL will be approved for 8 weeks assuming all other criteria are met. This criteria does not include the use of Sovaldi (sofosbuvir), and requests for Sovaldi (sofosbuvir) in combination with Olysio (simeprevir) which will not be approved. For the use of Sovaldi (sofosbuvir) see Sovaldi specific criteria. For the use of Olysio in combination with peginterferon and ribavirin, see Hepatitis C First Generation criteria. For hepatocellular carcinoma patients, see Sovaldi (sofosbuvir) specific criteria. TARGET DRUGS Preferred Agent(s) Harvoni® (ledipasvir/sofosbuvir) Nonpreferred Agent(s) Viekira Pak (ombitasvir/paritaprevir/ritonavir + dasabuvir) PRIOR AUTHORIZATION CRITERIA FOR APPROVAL Harvoni (ledipasvir/sofosbuvir) will be approved when the following criteria are met: 1. The patient has a diagnosis of chronic hepatitis C confirmed by serological markers AND 2.
    [Show full text]
  • Remdesivir Targets a Structurally Analogous Region of the Ebola Virus and SARS-Cov-2 Polymerases
    Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases Michael K. Loa,1, César G. Albariñoa, Jason K. Perryb, Silvia Changb, Egor P. Tchesnokovc,d, Lisa Guerreroa, Ayan Chakrabartia, Punya Shrivastava-Ranjana, Payel Chatterjeea, Laura K. McMullana, Ross Martinb, Robert Jordanb,2, Matthias Göttec,d, Joel M. Montgomerya, Stuart T. Nichola, Mike Flinta, Danielle Porterb, and Christina F. Spiropouloua,1 aViral Special Pathogens Branch, US Centers for Disease Control and Prevention, Atlanta, GA 30329; bGilead Sciences Inc., Foster City, CA 94404; cDepartment of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2E1, Canada; and dLi Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2E1, Canada Edited by Peter Palese, Icahn School of Medicine at Mount Sinai, New York, NY, and approved September 7, 2020 (received for review June 14, 2020) Remdesivir is a broad-spectrum antiviral nucleotide prodrug that remdesivir-selected EBOV lineages; this mutation resulted in a has been clinically evaluated in Ebola virus patients and recently nonconservative amino acid substitution at residue 548 (F548S) in received emergency use authorization (EUA) for treatment of the fingers subdomain of the EBOV L RdRp. We examined this COVID-19. With approvals from the Federal Select Agent Program mutation in several contexts: a cell-based minigenome, a cell-free and the Centers for Disease Control and Prevention’s Institutional biochemical polymerase assay, as well as in a full-length infectious Biosecurity Board, we characterized the resistance profile of recombinant EBOV. In the context of the infectious virus, the F548S remdesivir by serially passaging Ebola virus under remdesivir se- substitution recapitulated the reduced susceptibility phenotype to lection; we generated lineages with low-level reduced susceptibil- remdesivir, and potentially showed a marginal decrease in viral fit- ity to remdesivir after 35 passages.
    [Show full text]
  • TITLE PAGE COVID-19 Treatment
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 26 March 2020 doi:10.20944/preprints202003.0378.v1 Peer-reviewed version available at International Journal of Antimicrobial Agents 2020; doi:10.1016/j.ijantimicag.2020.106080 TITLE PAGE COVID-19 Treatment: Close to a Cure? – A Rapid Review of Pharmacotherapies for the Novel Coronavirus 1. Yang Song, PharmD, BCPS Department of Pharmacy Services CHI Franciscan Health-St. Joseph Medical Center Tacoma, WA 98405 [email protected] 2. Min Zhang, PharmD, BCPS Department of Pharmacy Services Boston Medical Center Boston, MA 02118 3. Ling Yin, PharmD, PhD, BCPS, BCOP Department of Pharmacy Services AdventHealth Celebration Cancer Institute Celebration, FL 34747 4. Kunkun Wang, PharmD Department of Pharmacy Services Fairbanks Memorial Hospital Fairbanks, AK 99701 5. Yiyi Zhou, PharmD Department of Pharmacy Services Beijing United Family Hospital Beijing, China 100016 6. Mi Zhou, MM Department of Pharmacy Services Children’s Hospital of Soochow University Suzhou, China 215000 7. Yun Lu, PharmD, MS Associate Clinical Professor, University of Minnesota Department of Pharmacy Services Hennepin County Medical Center Minneapolis, MN 55415 1 © 2020 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 26 March 2020 doi:10.20944/preprints202003.0378.v1 Peer-reviewed version available at International Journal of Antimicrobial Agents 2020; doi:10.1016/j.ijantimicag.2020.106080 Abstract Currently, there is no specific treatment for COVID-19 proven by clinical trials. WHO and CDC guidelines therefore endorse supportive care only. However, frontline clinicians have been applying several virus- based and host-based therapeutics in order to combat SARS-CoV-2.
    [Show full text]
  • An Examination of COVID-19 Medications' Effectiveness
    healthcare Review An Examination of COVID-19 Medications’ Effectiveness in Managing and Treating COVID-19 Patients: A Comparative Review Mahmoud Al-Masaeed 1,* , Mohammad Alghawanmeh 2, Ashraf Al-Singlawi 3 , Rawan Alsababha 4 and Muhammad Alqudah 1 1 Faculty of Health and Medicine, University of Newcastle, Callaghan 2308, Australia; [email protected] 2 Faculty of Pharmacy, Philadelphia University, Amman 19392, Jordan; [email protected] 3 Independent Scholar, Amman 11731, Jordan; [email protected] 4 School of nursing and Midwifery, Western Sydney University, Sydney 2560, Australia; [email protected] * Correspondence: [email protected] Abstract: Background: The review seeks to shed light on the administered and recommended COVID- 19 treatment medications through an evaluation of their efficacy. Methods: Data were collected from key databases, including Scopus, Medline, Google Scholar, and CINAHL. Other platforms included WHO and FDA publications. The review’s literature search was guided by the WHO Citation: Al-Masaeed, M.; solidarity clinical trials for COVID-19 scope and trial-assessment parameters. Results: The findings Alghawanmeh, M.; Al-Singlawi, A.; indicate that the use of antiretroviral drugs as an early treatment for COVID-19 patients has been Alsababha, R.; Alqudah, M. An useful. It has reduced hospital time, hastened the clinical cure period, delayed and reduced the Examination of COVID-19 need for mechanical and invasive ventilation, and reduced mortality rates. The use of vitamins, Medications’ Effectiveness in minerals, and supplements has been linked to increased immunity and thus offering the body a Managing and Treating COVID-19 fighting chance. Nevertheless, antibiotics do not correlate with improving patients’ wellbeing and Patients: A Comparative Review.
    [Show full text]